ATE426174T1 - Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten - Google Patents

Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten

Info

Publication number
ATE426174T1
ATE426174T1 AT06118062T AT06118062T ATE426174T1 AT E426174 T1 ATE426174 T1 AT E426174T1 AT 06118062 T AT06118062 T AT 06118062T AT 06118062 T AT06118062 T AT 06118062T AT E426174 T1 ATE426174 T1 AT E426174T1
Authority
AT
Austria
Prior art keywords
body fluids
beta oligomers
oligomers
detecting amyloid
amyloid
Prior art date
Application number
AT06118062T
Other languages
English (en)
Inventor
Santos Alexander Navarrete
Gerald Bihm
Original Assignee
Vista Ventures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vista Ventures Gmbh filed Critical Vista Ventures Gmbh
Application granted granted Critical
Publication of ATE426174T1 publication Critical patent/ATE426174T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AT06118062T 2006-07-28 2006-07-28 Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten ATE426174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06118062A EP1882944B1 (de) 2006-07-28 2006-07-28 Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten

Publications (1)

Publication Number Publication Date
ATE426174T1 true ATE426174T1 (de) 2009-04-15

Family

ID=37189402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06118062T ATE426174T1 (de) 2006-07-28 2006-07-28 Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten

Country Status (9)

Country Link
US (1) US20100129847A1 (de)
EP (1) EP1882944B1 (de)
JP (1) JP5009987B2 (de)
AT (1) ATE426174T1 (de)
AU (1) AU2007278422A1 (de)
CA (1) CA2693212A1 (de)
DE (1) DE602006005806D1 (de)
ES (1) ES2323725T3 (de)
WO (1) WO2008012101A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
WO2011092796A1 (ja) * 2010-01-28 2011-08-04 パナソニック株式会社 アミロイドβ測定方法
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
ES2398646T3 (es) 2010-07-24 2013-03-20 F. Hoffmann-La Roche Ag Estabilización de la interleuquina-6 en soluciones de suero
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
GB201411616D0 (en) * 2014-06-30 2014-08-13 Cambridge Entpr Ltd Diagnosis and treatment of neurodegenerative disorders
AU2015311836B2 (en) * 2014-09-05 2021-03-11 Presympto, Inc. Methods for detecting amyloid beta oligomers
WO2017056905A1 (ja) 2015-09-29 2017-04-06 浜松ホトニクス株式会社 アミロイドβオリゴマーの検出方法、アミロイドβオリゴマー検出装置及びアミロイドβオリゴマー検出プログラム
HK1257425A1 (zh) * 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
US11536731B2 (en) 2017-01-23 2022-12-27 Rensselaer Polytechnic Institute Systems and methods for binding amyloid fibrils using fluorescent protein
WO2020231774A1 (en) * 2019-05-10 2020-11-19 Quest Diagnostics Investments Llc MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE59805338D1 (de) * 1997-09-19 2002-10-02 Evotec Ag Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen
AU3772199A (en) * 1998-05-01 1999-11-23 University Of Tennessee Research Corporation, The Flow cytometric characterization of amyloid fibrils
DE19952955A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Charakterisierung und zur Auftrennung von molekularen Assoziaten
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
WO2005025516A2 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
WO2008012101A1 (en) 2008-01-31
EP1882944A1 (de) 2008-01-30
CA2693212A1 (en) 2008-01-31
JP2009544954A (ja) 2009-12-17
EP1882944B1 (de) 2009-03-18
ES2323725T3 (es) 2009-07-23
AU2007278422A1 (en) 2008-01-31
US20100129847A1 (en) 2010-05-27
DE602006005806D1 (de) 2009-04-30
JP5009987B2 (ja) 2012-08-29

Similar Documents

Publication Publication Date Title
DE602006005806D1 (de) Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten
NL301089I2 (nl) imlifidase
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
IL225386A (en) Method for diagnosis of cancer by detecting an ereg protein
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
NL300919I2 (nl) Brodalumab
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
CR20150016A (es) Anticuerpo monoclonal
NO20075671L (no) Neurodegenerative markorer for psykiatriske tilstander
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
ATE539060T1 (de) Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
EA201100231A1 (ru) Диагностический анализ на основе антител
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
DE602007007923D1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
EA201300130A1 (ru) Способ лечения болезни альцгеймера
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
EP2486407A4 (de) Verfahren zur diagnose von primärer biliärer cholangitis (pbc) mithilfe neuer autoantigene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties